Deutsche Bank AG set a $19.00 target price on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research note published on Monday, July 17th. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
Several other equities research analysts also recently commented on the company. Stifel Nicolaus reissued a buy rating and issued a $35.00 price objective (down previously from $45.00) on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 17th. Royal Bank Of Canada reissued a sector perform rating and set a $18.00 target price (down from $21.00) on shares of Valeant Pharmaceuticals International in a report on Thursday, March 23rd. Piper Jaffray Companies reaffirmed an outperform rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, April 14th. Scotiabank lifted their price target on Valeant Pharmaceuticals International from $12.00 to $14.00 and gave the company a sector perform rating in a research note on Wednesday, May 10th. Finally, J P Morgan Chase & Co restated a hold rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, May 9th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $16.96.
Valeant Pharmaceuticals International (VRX) opened at 15.13 on Monday. The company’s 50-day moving average is $16.16 and its 200 day moving average is $13.34. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74. The company’s market cap is $5.26 billion.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $1.93. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The firm had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. During the same quarter in the prior year, the firm posted ($1.08) EPS. The business’s revenue was down 11.1% on a year-over-year basis. Equities analysts forecast that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Given a $19.00 Price Target at Deutsche Bank AG” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/07/deutsche-bank-ag-analysts-give-valeant-pharmaceuticals-international-inc-nysevrx-a-19-00-price-target-updated-updated.html.
In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 20,000 shares of the firm’s stock in a transaction on Thursday, May 11th. The shares were acquired at an average cost of $13.90 per share, with a total value of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares in the company, valued at $980,950.80. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.87% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the company. Sigma Planning Corp purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at about $184,000. Nationwide Fund Advisors boosted its stake in shares of Valeant Pharmaceuticals International by 3.8% in the first quarter. Nationwide Fund Advisors now owns 51,500 shares of the specialty pharmaceutical company’s stock valued at $568,000 after buying an additional 1,900 shares during the period. Cambridge Advisors Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 0.6% in the first quarter. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company’s stock valued at $140,000 after buying an additional 75 shares during the period. Columbus Circle Investors boosted its stake in shares of Valeant Pharmaceuticals International by 24.6% in the first quarter. Columbus Circle Investors now owns 75,252 shares of the specialty pharmaceutical company’s stock valued at $830,000 after buying an additional 14,880 shares during the period. Finally, Academy Capital Management Inc. TX boosted its stake in shares of Valeant Pharmaceuticals International by 19.5% in the first quarter. Academy Capital Management Inc. TX now owns 641,738 shares of the specialty pharmaceutical company’s stock valued at $7,078,000 after buying an additional 104,844 shares during the period. 50.53% of the stock is currently owned by hedge funds and other institutional investors.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
